Видео ютуба по тегу Ctl019

Dr. Grupp discusses CTL019
Dr. Grupp discusses CTL019
Dr. Roboz on Impact of CTL019 in ALL
Dr. Roboz on Impact of CTL019 in ALL
The Use of CTL019 in Lymphoma
The Use of CTL019 in Lymphoma
CTL019 Simulation Using Benchling
CTL019 Simulation Using Benchling
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
CAR-T cell Therapy for Leukemia patients
CAR-T cell Therapy for Leukemia patients
Prof. Gilles Salles: Interim analysis of the JULIET study of CTL019 in R/R DLBCL
Prof. Gilles Salles: Interim analysis of the JULIET study of CTL019 in R/R DLBCL
Six-month follow up of CTL019 for diffuse large B-cell lymphoma
Six-month follow up of CTL019 for diffuse large B-cell lymphoma
CAR-T - персональное лекарство от РАКА #меднавигатор
CAR-T - персональное лекарство от РАКА #меднавигатор
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
How does CAR T Cell therapy work?
How does CAR T Cell therapy work?
The Promise and Potential of CAR T Cell Therapy in Rheumatology
The Promise and Potential of CAR T Cell Therapy in Rheumatology
Genetically Modified Immune Cells Attack Leukemia in Adults and Children
Genetically Modified Immune Cells Attack Leukemia in Adults and Children
A Look at How CAR T Cell Therapy Works
A Look at How CAR T Cell Therapy Works
Prof. Stephen J. Schuster, M.D.: CTL019 in R/R DLBCL – interim results interview from ICML 2017
Prof. Stephen J. Schuster, M.D.: CTL019 in R/R DLBCL – interim results interview from ICML 2017
ASH2014: Stephan A. Grupp - CAR targeting CTL019 in Children with Relapsed, Refractory ALL
ASH2014: Stephan A. Grupp - CAR targeting CTL019 in Children with Relapsed, Refractory ALL
Novartis’ CAR-T Therapy Kymriah Secures Second FDA Approval in Lymphoma
Novartis’ CAR-T Therapy Kymriah Secures Second FDA Approval in Lymphoma
Clinical data for CD19-directed CAR T-cell products in ALL
Clinical data for CD19-directed CAR T-cell products in ALL
Lecture: Creating A Universal Donor-Derived Cell Therapy, Thierry Wurch
Lecture: Creating A Universal Donor-Derived Cell Therapy, Thierry Wurch
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL